From Lab to Market: Sano Turns Computational Medicine Research Into Companies 

First Spin-Off Launched, Pipeline Growing

Sano Centre for Computational Personalised Medicine has launched its first spin-off, NEUREVEAL, turning years of computational-medicine research into an independent company. It is the first venture to emerge from Sano’s technology-transfer model demonstrating how scientific results can move beyond the research environment and towards real-world use.

NEUREVEAL was founded to bring AI-based analysis of brain data — from EEG and neuroimaging — toward clinical use, supporting faster and more precise detection and characterisation of neurological conditions. The company grew out of research led at Sano by Rosmary Blanco (PhD Student in Computational Neuroscience) and Luca Gherardini (Postdoctoral Researcher in Computational Intelligence), and its launch in August 2026 makes it the first company to spin out of the Centre since its founding in 2019.

For Sano, this first spin-off means more than a single company. Translating research to market is one of the Centre’s core strategic domains, and NEUREVEAL demonstrates that the full path — from a scientist’s idea, through validation, to an incorporated business — now works in practice. It shows that computational-medicine research done in Kraków can move out of the lab and into the healthcare market, where it can reach patients and clinicians.

Crucially, the founders are the scientists themselves. Rather than licensing ideas away, Sano supports its researchers in developing their own concepts into companies — combining scientific depth with entrepreneurship and innovation, two more of the Centre’s strategic pillars. NEUREVEAL’s founding team, Rosmary Blanco and Luca Gherardini, developed the company’s core methods through their research in computational neuroscience and computational intelligence at Sano.

NEUREVEAL is the first of several. More spin-offs are currently in the pipeline at Sano, spanning areas such as medical imaging, AI diagnostics and digital health, each led by Sano scientists commercialising their own research.

For partners, investors and clinical collaborators, the message is simple: Sano is now a source not only of research and talent, but of investable, science-based companies in computational and personalised medicine — and the pipeline is open.

To learn more about collaborating with Sano’s spin-offs or supporting the next cohort of founders, contact Katarzyna Nicholson (k.nicholson@sanoscience.org).